25I-NBMD

From Self-sufficiency
Jump to: navigation, search
25I-NBMD
200px
Systematic (IUPAC) name
2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2,3-methylenedioxyphenyl)methyl]ethanamine
Chemical data
Formula C18H20INO4
Molar mass 441.259 g/mol[[Script error: No such module "String".]]
Script error: No such module "collapsible list".
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

25I-NBMD (NBMD-2C-I) is a derivative of the phenethylamine hallucinogen 2C-I, discovered in 2006 by a team at Purdue University led by David Nichols. It acts as a potent agonist for the 5HT2A receptor with a Ki of 0.049nM at the human 5HT2A receptor.[1][2]


See also

References

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />


  1. Braden MR, Parrish JC, Naylor JC, Nichols DE. Molecular interaction of serotonin 5-HT2A receptor residues Phe339(6.51) and Phe340(6.52) with superpotent N-benzyl phenethylamine agonists. Molecular Pharmacology. 2006 Dec;70(6):1956-64. PMID 17000863
  2. Michael Robert Braden PhD. Towards a biophysical understanding of hallucinogen action. Purdue University 2007.